ArticleJournal of autoimmunity2016
Predictors of slow progression to diabetes in children with multiple islet autoantibodies.
Article in Journal of autoimmunity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Age-related heterogeneity of type 1 diabetes mellitus in children: a single-center retrospective study.World journal of pediatrics : WJP · 2026Article
- Evaluation of proinsulin(F25D) as a targeting ligand for insulin-binding B cells in autoimmune diabetes.Drug delivery and translational research · 2026Article
- Stage 1 type 1 diabetes memory B lymphocytes transcriptionally differ from healthy controls and harbor insulin-binding specificities.ImmunoHorizons · 2025Article
- Autoimmune Type 1 Diabetes in the Era of Disease-Modifying Immune Therapy.Diabetes/metabolism research and reviews · 2025Review
- Dia-B-Ties: B Cells in the Islet-Immune-Cell Interface in T1D.Biomolecules · 2025Review
- Understanding Islet Autoantibodies in Prediction of Type 1 Diabetes.Journal of the Endocrine Society · 2023Review
- Identification of an anergic BND cell-derived activated B cell population (BND2) in young-onset type 1 diabetes patients.The Journal of experimental medicine · 2023Article
- Quantifying the utility of islet autoantibody levels in the prediction of type 1 diabetes in children.Diabetologia · 2023Article
- Islet Autoantibody Levels Differentiate Progression Trajectories in Individuals With Presymptomatic Type 1 Diabetes.Diabetes · 2022Article
- Islet Autoantibody Level Distribution in Type 1 Diabetes and Their Association With Genetic and Clinical Characteristics.The Journal of clinical endocrinology and metabolism · 2022Article
- Islet Autoantibody Type-Specific Titer Thresholds Improve Stratification of Risk of Progression to Type 1 Diabetes in Children.Diabetes care · 2022Article
- Ten years follow up of first degree relatives of type 1 diabetes patients: presence of autoimmune biomarkers and the progression to diabetes in a retrospective cohort.Archives of endocrinology and metabolism · 2021Article
- Diagnostic Capabilities of Islet Autoantibodies in Children with New-Onset Type 1 Diabetes Mellitus and Healthy Siblings.Sovremennye tekhnologii v meditsine · 2021Article
- The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening.Diabetologia · 2020Article
- Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.Diabetes care · 2020Article
- Shared and unique immune alterations in pre-clinical autoimmunity.Current opinion in immunology · 2019Review
- What Have Slow Progressors Taught Us About T1D-Mind the Gap!Current diabetes reports · 2019Review
- Extracellular Vesicles in Type 1 Diabetes: Messengers and Regulators.Current diabetes reports · 2019Review
- Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk.Diabetologia · 2018Article
- Increased Effector Memory Insulin-Specific CD4Diabetes · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Although most children with multiple islet autoantibodies develop type 1 diabetes, rate of progression is highly variable. The goal of this study was to explore potential factors involved in rate of progression to diabetes in children with multiple islet autoantibodies. The Diabetes Autoimmunity Study in the Young (DAISY) has followed 118 children with multiple islet autoantibodies for progression to diabetes. After excluding 27 children currently diabetes-free but followed for <10 years, the study population was grouped into: rapid progressors (N = 39) who developed diabetes in <5 years; moderate progressors (N = 25), diagnosed with diabetes within 5-10 years; and slow progressors (N = 27), diabetes-free for >10 years. Islet autoimmunity appeared at 4.0 ± 3.5, 3.2 ± 1.8 and 5.8 ± 3.1 years of age in rapid, moderate and slow progressors, respectively (p = 0.006). Insulin autoantibody levels were lower in slow progressors compared to moderate and rapid progressors. The groups did not differ by gender, ethnicity, family history, susceptibility HLA and non-HLA genes. The rate of development of individual islet autoantibodies including mIAA, GADA, IA-2A and ZnT8A were all slower in the slow versus moderate/rapid progressors. In multivariate analyses, older age at seroconversion and lower initial mIAA levels independently predicted slower progression to diabetes. Later onset of islet autoimmunity and lower autoantibody levels predicted slower progression to diabetes among children with multiple islet autoantibodies. These factors may need to be considered in the design of trials to prevent type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.